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Purpose: Dipeptidyl-peptidase-4 (DPP-4) inhibitors are known to increase insulin secretion
and beta cell proliferation in rodents. To investigate the effects on human beta cells in vivo,
we utilize immunodeficient mice transplanted with human islets. The study goal was to determine the efficacy of alogliptin, a DPP-4 inhibitor, to enhance human beta cell function and
proliferation in an in vivo context using diabetic immunodeficient mice engrafted with human
pancreatic islets.
Methods: Streptozotocin-induced diabetic NOD-scid IL2rg null (NSG) mice were transplanted
with adult human islets in three separate trials. Transplanted mice were treated daily by gavage
with alogliptin (30 mg/kg/day) or vehicle control. Islet graft function was compared using
glucose tolerance tests and non-fasting plasma levels of human insulin and C-peptide; beta cell
proliferation was determined by bromodeoxyuridine (BrdU) incorporation.
Results: Glucose tolerance tests were significantly improved by alogliptin treatment for mice
transplanted with islets from two of the three human islet donors. Islet-engrafted mice treated
with alogliptin also had significantly higher plasma levels of human insulin and C-peptide
compared to vehicle controls. The percentage of insulin+BrdU+ cells in human islet grafts
from alogliptin-treated mice was approximately 10-fold more than from vehicle control mice,
consistent with a significant increase in human beta cell proliferation.
Conclusion: Human islet-engrafted immunodeficient mice treated with alogliptin show
improved human insulin secretion and beta cell proliferation compared to control mice engrafted
with the same donor islets. Immunodeficient mice transplanted with human islets provide a useful
model to interrogate potential therapies to improve human islet function and survival in vivo.
Keywords: human islet transplant, DPP-4 inhibitor, glucose tolerance, plasma insulin
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Glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists increase glucosedependent insulin secretion, beta cell viability, and activate proliferative pathways
that lead to increased beta cell mass in rodents.1,2 In clinical trials with type 2 diabetic
patients, GLP-1 receptor agonists lowered both fasting and postprandial glucose
concentrations,3,4 although no improvement (as measured by C-peptide secretion)
was observed in patients with long-standing type 1 diabetes.5 Glycemic control of
patients taking metformin or sulfonylurea was also improved in conjunction with
GLP-1 receptor agonists.6–8 In clinical trials with agents that block GLP-1 degradation, such as dipeptidyl-peptidase-4 (DPP-4) inhibitors, fasting and postprandial
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glucose levels of patients are also lowered, consistent
with improved pancreatic beta cell function.9–11 However,
human islet function remains difficult to assess directly
due to inaccessibility of relevant tissues, as well as inherent variability between patients. An alternative method to
investigate human islet function in vivo is to transplant
human islets into streptozotocin (STZ)-induced diabetic
NOD-scid IL2rg null (NSG) mice.12,13
Recently, a new DPP-4 inhibitor, alogliptin, has been
developed14 and its safety and efficacy in treating type 2 diabetes (T2D) patients is being investigated.15–17 Alogliptin was
found to improve glycemic control in patients with poorly
controlled diabetes as evidenced by reduced fasting blood
glucose and hemoglobin A1c levels.17 We hypothesized
that alogliptin treatment of diabetic immunodeficient mice
engrafted with human islets will measurably enhance the
proliferation and insulin secretory function of human beta
cells in an in vivo setting. The goal of this study was to utilize
STZ-induced diabetic NSG mice transplanted with human
pancreatic islets to determine the ability of alogliptin to
enhance human beta cell function and proliferation.

Material and methods
Mice and diabetes induction
NOD.cg-PrkdcscidIl2rgtm1Wjl/SzJ (abbreviated as NOD-scid
IL2rγ  null or NSG) mice from The Jackson Laboratory (Bar
Harbor, ME, USA) were housed in a specific pathogen-free
facility and maintained12 in accordance with the Institutional Animal Care and Use Committee of the University of
Massachusetts Medical School; the NSG is an immunodeficient mouse that can be engrafted with functional human
cells and tissues for in vivo studies.18
Male NSG mice (8–12 weeks old) received a single
intraperitoneal injection of 160 mg/kg STZ (SigmaAldrich, St Louis, MI, USA) to induce diabetes (blood
glucose .300 mg/dL on two consecutive days). Blood glucose was monitored with an ACCU-CHEK Aviva Plus glucometer (Roche Diagnostics, Indianapolis, IL, USA). After
diabetes was confirmed, mice were given insulin implants
(LinShin Canada, Inc, Toronto, ON, Canada) until human
islets were available for transplant.

Human islet transplantation
Human islets were obtained from the Integrated Islet Distribution Program under protocols approved by the Institutional
Review Board of the University of Massachusetts Medical
School. Insulin implants were removed upon transplant of
2000 human islet equivalents (IEQs). Briefly, the mice were
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anesthetized and prepared for surgery. The skin and muscle
layer over the spleen was incised, and the kidney was gently
externalized with forceps. The human islets (suspended in
Connaught Medical Research Laboratories plus 1% fetal
bovine serum [FBS]) were injected into the subrenal capsular space using a SURFLO winged infusion set (23 g ×
3/4 inch; Terumo Medical Corporation, Somerset, NJ, USA).
The kidney was then replaced in the abdominal cavity, the
muscle was sutured, and the skin was closed with an Autoclip
wound closure system (Thermo Fisher Scientific, Houston,
TX, USA).

Alogliptin treatment
One day post-transplant, diabetic mice that received islets
from a single donor were randomized into two groups of five
mice each and treated daily by oral gavage with 30 mg/kg/day
alogliptin (provided by Takeda Pharmaceuticals North
America, Deerfield, IL, USA) or equivalent volume of
vehicle (phosphate-buffered saline [PBS]). The 30 mg/kg/day
dosage is mid-range between doses (15 and 45 mg/kg) that
have previously been shown to be effective in restoring beta
cell mass and islet function in two different mouse models
of diabetes.19,20 Daily treatments were continued until graft
removal at 32–39 days post-transplant.

Glucose tolerance test
Mice were fasted overnight and blood glucose was measured
following intraperitoneal injection of glucose (2.0 g/kg body
weight). Glucose area under the curve (AUC) was calculated
by the trapezoidal rule.

Human insulin and C-peptide analysis
Heparinized blood from nonfasting mice was collected with
protease inhibitor (aprotinin; Sigma-Aldrich) at 3–4 weeks
post-transplant; plasma was stored at −80°C until analyzed
by human-specific enzyme-linked immunosorbent assay
(ELISA; ALPCO Diagnostics, Salem, NH, USA).

Bromodeoxyuridine treatment, histology,
and immunofluorescence staining
Human islet-engrafted mice were provided drinking water
containing 0.8 mg/mL of bromodeoxyuridine (BrdU) ad
libitum for 7 days prior to recovery of the graft-bearing
kidney. Islet graft-bearing kidneys were fixed in 10% neutralbuffered formalin. Paraffin-embedded sections were dualstained with guinea pig anti-insulin (Dako, Carpinteria, CA,
USA) and rat anti-BrdU (Accurate Chemical, Westbury, NJ,
USA); secondary Alexa-Fluor and Cy-5 antibodies and 4′,6-
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diamidino-2-phenylindole (DAPI) were from Sigma-Aldrich.
Insulin+ and insulin+BrdU+ cells were visualized by fluorescence microscopy (Zeiss, New York, NY, USA); counts
were performed with MetaMorph (Molecular Devices,
Downington, PA, USA).

Statistical analyses
Time-course data were analyzed by repeated measures
analysis of variances (ANOVA) with Bonferroni post-hoc
test; remaining data were analyzed with Mann-Whitney or
t-test as appropriate (GraphPad Prism, San Diego, CA, USA).
P-values ,0.05 were considered significant.

Results
Normoglycemic NSG mice (blood glucose ,150 mg/dL)
were made chemically diabetic with STZ treatment. After
diabetes was confirmed, mice were given subcutaneous
insulin implants to maintain the health of the animals until
human islets were available for transplant. Three independent studies were performed with human islets from three
different donors. The islet donor characteristics are shown
in Table 1. Daily alogliptin (or vehicle control) treatments
were started at day 1 post-transplant. Normoglycemia was
restored within 1 week for diabetic mice transplanted with
2000 IEQs from both Donors 1 and 2, regardless of treatment status (Figure 1A). In contrast, mice transplanted with
2000 IEQs from Donor 3 and treated with alogliptin showed
a significant acceleration in the lowering of blood glucose
levels relative to mice receiving vehicle alone. At the end of
the study period, all mice in all groups were normoglycemic.
As expected, the body weights (Figure 1B) of alogliptintreated mice transplanted with Donor 3 islets significantly
improved compared to the vehicle control mice.
Daily alogliptin treatment also significantly improved
glucose tolerance tests (GTTs) in mice engrafted with islets
from two of the three human donors (Figure 2A); this was also
demonstrated with glucose AUC measurements (Figure 2B).
Consistent with improved GTTs, the non-fasting plasma levels
of both human insulin (Figure 3A) and C-peptide (Figure 3B)
were significantly higher in islet-engrafted mice treated with
Table 1 Demographic characteristics of human islet donors
Age, years
Sex (M/F)
Body weight, kg
BMI, kg/m2

Donor 1

Donor 2

Donor 3

51
F
69.0
23.9

53
nr
nr
27.3

65
M
nr
24.5

Abbreviations: BMI, body mass index; F, female; M, male; nr, not recorded.
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alogliptin compared to vehicle-treated mice. When comparing
individual donors, human insulin and C-peptide values following alogliptin treatment were similar between Donors 2
and 3, consistent with the recipient mice blood glucose levels
(mean =89 and 82 mg/dL, respectively) obtained at the time
of analysis. Interestingly, although blood glucose levels were
higher in control mice engrafted with islets from Donor 3
(mean =198 mg/dL) than from Donor 2 (mean =87 mg/dL),
human insulin values from Donor 3 engrafted mice were
somewhat elevated compared to Donor 2 (Figure 3A), whereas
C-peptide levels were similar (Figure 3B).
To determine whether alogliptin treatment enhances beta
cell proliferation within the human islet grafts, the mice were
supplied with BrdU in their drinking water. Upon surgical
removal of the graft-bearing kidney all mice became acutely
hyperglycemic (blood glucose .500 mg/dL), thus documenting that the human islet graft was responsible for maintaining
normoglycemia. The recovered islet grafts were subsequently
immunostained for insulin and BrdU. Immunofluorescent
analysis of human islet grafts from all three donors demonstrated that the percentage of insulin+BrdU+ cells from
alogliptin-treated mice was significantly higher than from
vehicle control mice (Figure 4). Representative islet graft sections from a vehicle control and an alogliptin-treated mouse
engrafted with islets from Donor 1 are shown in Figure 5A
and B, respectively. Although BrdU+ staining indicative of
proliferating cells was readily detectable in all islet graft sections (Figure 5A), only two of six human islet grafts analyzed
from control mice (one each from Donors 1 and 3) had any
detectable insulin+BrdU+ cells. In contrast, insulin+BrdU+
cells (Figure 5B) were present in five of six islet grafts analyzed (from all three human islet donors) in alogliptin-treated
mice. When totaled, the average proliferation of human beta
cells in all islet grafts analyzed from alogliptin-treated mice
was 0.58% (44 of 7591 insulin+ cells), a 10-fold increase
from that observed in islet grafts from vehicle control mice
(0.056%, 2 of 3542 insulin+ cells).

Discussion
This study investigated the therapeutic efficacy of alogliptin,
a DPP-4 inhibitor, on human beta cell function and proliferation in diabetic immunodeficient NSG mice engrafted
with adult human islets. Because multiple cohorts of mice
can be transplanted with islets from a single human donor,
donor-specific beta cell function can be compared directly
in islet-engrafted control and treated mice, thus eliminating
variability in donor-to-donor islet isolation and handling,
as well as differences due to age, sex, body mass index

submit your manuscript | www.dovepress.com
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Figure 1 Comparison of blood glucose and body weights of control and alogliptin-treated mice engrafted with human islets.
Notes: Diabetic NSG mice were transplanted with human islets from three individual donors and treated daily by gavage with alogliptin (n=5, each donor) or vehicle control
(n=5, each donor). (A) Blood glucose and (B) body weight of the mice were monitored over the treatment period on the days indicated; shown are mean ± standard error
of the mean. *P<0.05.
Abbreviation: NSG, NOD-scid IL2rg null.
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Figure 2 Comparison of glucose tolerance tests in control and alogliptin-treated mice engrafted with human islets.
Notes: Human islet engrafted mice were treated daily with alogliptin or vehicle control. (A) A glucose tolerance test was administered to mice engrafted with islets from
Donors 1 and 2 at days 21 and 19, respectively, following islet transplantation. The glucose tolerance test on mice engrafted with Donor 3 islets was administered at day 31
when the blood glucose of vehicle control mice was approaching normoglycemia. *P<0.05. (B) Glucose AUC for the 120 min glucose tolerance test shown in (A); n=4 mice
per group for each donor; shown are mean ± standard error of the mean.
Abbreviations: AUC, area under the curve; NS, not significant.
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B

*P<0.05
1,200

Human C-peptide (ng/mL)

Human insulin (pg/mL)

A

800
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0
Vehicle

Alogliptin

*P<0.05
5
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3
2
1
0
Vehicle
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Figure 3 Comparison of human insulin and C-peptide levels in control and alogliptin-treated mice engrafted with human islets.
Notes: Non-fasting blood was collected from NSG mice engrafted with human islets from Donors 2 and 3 on days 26 and 24, respectively, following transplant. Plasma levels
of (A) human insulin and (B) human C-peptide from individual vehicle control (n=8 total, 4 per islet donor) or alogliptin-treated (n=7 total, 4 from Donor 2, and 3 from
Donor 3) mice are shown. Plasma samples from mice engrafted with islets from Donor 1 were not available for analysis. Each dot or triangle represents data obtained from
an individual mouse engrafted with human islets from Donors 2 or 3, respectively; horizontal bar indicates the mean for each group.
Abbreviation: NSG, NOD-scid IL2rg null.

(BMI), lifestyle, or pre-existing disease. In this study, we
utilized human islets derived from both male and female
islet donors, aged 51–65 years, with BMI between 24–28.
Here we report significant beneficial effects of alogliptin on
human beta cell proliferation, circulating levels of human
insulin and C-peptide, and glucose homeostasis of NSG mice
transplanted with adult human islets.
A recent study in a mouse model of diabetes demonstrated
similar beneficial effects of alogliptin to lower fasting and
postprandial blood glucose levels in diabetic mice.19 This
study also demonstrated an improvement in beta cell mass
and insulin content in pancreata of alogliptin-treated mice.19
Recently, alogliptin in combination with pioglitazone has been
reported to enhance regeneration of transplanted syngeneic

mouse islets and endogenous islets of STZ-diabetic mice.20
Although informative, such studies on mouse beta cells may
not accurately predict human beta cell responses due to differences in the architecture, signaling pathways, and relative
proportions of endocrine cells, as well as beta cell proliferative
capacity which is robust in young rodents but negligible in
humans, especially in individuals .30 years old.21,22
To circumvent potential discrepancies in therapeutic
outcome due to species differences, we utilized diabetic NSG
mice engrafted with human islets. We observed improved

A

B

*P<0.05

% insulin+BrdU+ cells

5
4
3
1.0
0.8
0.6
0.4

Vehicle

0.2
0.0
Vehicle

Alogliptin

Figure 4 Induction of human beta cell proliferation with alogliptin treatment of
islet engrafted mice. Percent human beta cell proliferation in islet grafts from vehicle
control (n=6 total, 2 per islet donor) and alogliptin-treated (n=6 total) mice.
Note: Each dot represents data obtained from a single islet graft from one mouse.
Abbreviation: BrdU, bromodeoxyuridine.
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Alogliptin

Figure 5 Insulin+BrdU+ beta cells in human islet grafts from alogliptin-treated mice.
Notes: Representative micrographs of human islets from a single donor (Donor 1)
engrafted in (A) vehicle control or (B) alogliptin-treated mice are shown. Top
panels show insulin (red) and BrdU (green) staining; bottom panels include nuclei
staining with DAPI (blue). Similar results were seen with islet grafts from Donors
2 and 3. Arrows show insulin+BrdU+ cells; arrowheads indicate insulin-negative
BrdU+ cells; cells were only counted as insulin+ if the staining was visible around the
entire perimeter of the nucleus.
Abbreviations: BrdU, bromodeoxyuridine; DAPI, 4′,6-diamidino-2-phenylindole.
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glucose tolerance tests in alogliptin-treated versus control
mice transplanted with human islets from two of three individual donors (including 65-year-old Donor 3). Because
our immunodeficient mice are exposed to the same diet and
housing conditions, we can effectively exclude the potential
contribution of such factors to glucose homeostasis and
suggest that alogliptin treatment directly enhances human
islet function.
Indeed, the improved glucose tolerance in human islet
engrafted mice treated with alogliptin is consistent with our
finding that plasma levels of human insulin and C-peptide
were also significantly increased in these alogliptin-treated
mice. We observed a 1.5-fold increase in human insulin
(742±106 versus 483±91 pg/mL) and a 1.8-fold increase
in human C-peptide (2.17±0.47 versus 1.18±0.22 ng/mL)
in alogliptin-treated versus control mice. This is strikingly
consistent with data from obese diabetic ob/ob mice, where
4 weeks of treatment with alogliptin increased plasma insulin
by 1.5–2.0 fold.23 Similar results were also reported in T2D
patients, in whom the homeostasis model assessment of
beta-cell function (HOMA-B) worsened with placebo, but
improved with alogliptin treatment.17
In rodents, DPP-4 inhibitors were reported to increase the
proliferation of beta cells.1,2,24 In our study, alogliptin treatment also stimulated human beta cell proliferation within the
islet grafts by approximately 10-fold, a similar magnitude
of induction that we and others have reported for engrafted
human beta cells in response to hyperglycemia.25,26 Together
these data may suggest that human beta cells, even from older
individuals, can be induced to proliferate in vivo in response
to certain inductive stimuli, albeit at a much lower level
than observed in rodents. Nonetheless, the small numbers
of proliferating beta cells cannot account for the significant
increase in plasma levels of human insulin and improved
glucose tolerance tests we observed. Speculatively, however,
longer-term alogliptin treatment in patients with T2D may
result in a small, but functionally relevant enhancement of
human beta cell mass that may add to other ameliorative
effects of alogliptin on islet function and survival to improve
the total therapeutic benefit.

Conclusion
In this study we demonstrate that human islet-engrafted
NSG mice treated with alogliptin show improved glucose
tolerance and increased human insulin secretion and beta
cell proliferation compared to islet-engrafted control mice.
Thus, immunodeficient mice transplanted with human islets
provide a useful model to interrogate potential therapies to
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improve human islet function and survival in an in vivo setting without putting patients at risk. In addition, the ability
to transplant multiple mice with human islets from a single
donor provides a powerful experimental paradigm to assess
potential mechanisms at play, which is limited in clinical
studies with human patients.
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